NCT06277245View on ClinicalTrials.gov

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

354

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

LNK01001

Capsule; Oral

DRUG

Placebo

Capsule; Oral

Trial Locations (1)

Unknown

Dermatological Hospital of Southern Medical University, Guangzhou

Sponsors
All Listed Sponsors
lead

Lynk Pharmaceuticals Co., Ltd

INDUSTRY